Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities

被引:29
|
作者
Chu, Chia-Yu [1 ,2 ]
Chen, Kuan-Yu [2 ,3 ]
Chang, John Wen-Cheng [4 ]
Wei, Yu-Feng [5 ,6 ]
Lee, Chih-Hung [7 ,8 ]
Wang, Wei-Ming [9 ,10 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Dermatol, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[4] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med,Div Hematol Oncol, Taoyuan, Taiwan
[5] I Shou Univ, Dept Internal Med, Kaohsiung, Taiwan
[6] E Da Hosp, Kaohsiung, Taiwan
[7] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[8] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[9] Triserv Gen Hosp, Dept Dermatol, Taipei, Taiwan
[10] Natl Def Med Ctr, Taipei, Taiwan
关键词
consensus; diagnosis; epidermal growth factor receptor; skin toxicities; tyrosine kinase inhibitors; CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; ADVERSE EVENTS; PHASE-III; CARBOPLATIN-PACLITAXEL; CUTANEOUS TOXICITIES; TREATMENT STRATEGIES; GEFITINIB; ERLOTINIB;
D O I
10.1016/j.jfma.2017.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan. Methods: All the consensus contents were voted on by the participating experts, with approval by no less than 75% required for inclusion. Results: The consensus provides a comprehensive overview of EGFR-TKI skin toxicities, including recent advances in identifying their causes and the processes by which they develop. Conclusion: All the consensus meeting attendees agreed that there are several major EGFR-TKI-related skin toxicities, including acneiform rash (i.e., papulopustular rash), xeroderma, pruritus, paronychia, stomatitis, mucositis, and hair changes (such as hair loss, slowed hair growth, and trichomegaly). The experts were also generally unanimous in their voting on the specific definitions, onset times, and care suggestions for each of those skin toxicities. Furthermore, the recommended treatment algorithms for the various skin toxicities were ultimately approved by 100% (15/15) of the consensus attendees. Copyright (C) 2017, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:413 / 423
页数:11
相关论文
共 50 条
  • [21] Effectiveness of Epidermal Growth Factor containing Moisture Cream for treatment of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)-induced cutaneous toxicities.
    Lee, Sung Yong
    Moon, Jae Young
    Lee, Sang Yeub
    Kim, Je Hyeong
    Shin, Chol
    Shim, Jae Jeong
    In, Kwang Ho
    Yoo, Se Hwa
    Kang, Kyung Ho
    Kim, Jun Suk
    Song, Hae Jun
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S895 - S895
  • [22] Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients
    Lee, Ji Su
    Woo, Jimin
    Kim, Tae Min
    Kim, Namkyu
    Keam, Bhumsuk
    Jo, Seong Jin
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [23] Epidermal growth factor receptor tyrosine kinase inhibitors
    M Ranson
    British Journal of Cancer, 2004, 90 : 2250 - 2255
  • [24] Epidermal growth factor receptor tyrosine kinase inhibitors
    Wakeling, AE
    CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 382 - 387
  • [25] Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
    Hirsh, V.
    Blais, N.
    Burkes, R.
    Verma, S.
    Croitoru, K.
    CURRENT ONCOLOGY, 2014, 21 (06) : 329 - 336
  • [26] Epidermal growth factor receptor tyrosine kinase inhibitors
    Ranson, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (12) : 2250 - 2255
  • [27] Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity
    Sibaud, V.
    Tournier, E.
    Roche, H.
    Del Giudice, P.
    Delord, J. P.
    Hubiche, T.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2016, 41 (01) : 34 - 37
  • [28] Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor
    McKillop, D
    Partridge, EA
    Kemp, JV
    Spence, MP
    Kendrew, J
    Barnett, S
    Wood, PG
    Giles, PB
    Patterson, AB
    Bichat, F
    Guilbaud, N
    Stephens, TC
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 641 - 649
  • [29] Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Chang, Youjin
    Kim, Seon Ye
    Choi, Yun Jung
    So, Kwang Sup
    Rho, Jin Kyung
    Kim, Woo Sung
    Lee, Jae Cheol
    Chung, Jin-Haeng
    Choi, Chang-Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2013, 75 (03) : 95 - 103
  • [30] Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog
    McKillop, D
    Partridge, EA
    Hutchison, M
    Rhead, SA
    Parry, AC
    Bardsley, J
    Woodman, HM
    Swaisland, HC
    XENOBIOTICA, 2004, 34 (10) : 901 - 915